BAK1 and ischemic cardiomyopathy: Therefore, conducting drug research targeting BAX/BAK for the treatment of ischemic cardiomyopathy may have broad prospects, with strategies such as nanoparticle-mediated cardiac targeting, AAV-based cardiac-specific promoters, and PROTACs technology representing promising approaches to enhance drug efficacy while minimizing clinical risks (Figure 6).